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Ewing’s sarcoma family of tumours comprises a group of very aggressive diseases that are potentially curable with multimodality
treatment. Despite the undoubted success of current treatment, approximately 30% of patients will relapse and ultimately die
of disease. The insulin-like growth factor 1 receptor (IGF-1R) has been implicated in the genesis, growth, proliferation, and the
development of metastatic disease in Ewing’s sarcoma. In addition, IGF1-R has been validated, both in vitro and in vivo,a sa
potential therapeutic target in Ewing’s sarcoma. Phase I studies of IGF-1R monoclonal antibodies reported several radiological
and clinical responses in Ewing’s sarcoma patients, and initial reports of several Phase II studies suggest that about a fourth of
the patients would beneﬁt from IGF-1R monoclonal antibodies as single therapy, with approximately 10% of patients achieving
objective responses. Furthermore, these therapies are well tolerated, and thus far severe toxicity has been rare. Other studies
assessing IGF-1R monoclonal antibodies in combination with traditional cytotoxics or other targeted therapies are expected.
Despite, the initial promising results, not all patients beneﬁt from IGF-1R inhibition, and consequently, there is an urgent need for
the identiﬁcation of predictive markers of response.
1.Introduction
Sarcomas represent a diverse group of tumours that arise
from connective tissue, and account for 12% of paediatric
malignancies and approximately 1% of all adult tumors [1–
3]. Signiﬁcant progress has been made in the classiﬁcation,
staging, and multimodal treatment of these heterogeneous
conditions including: surgical advances in functional preser-
vation,theuseofradiotherapyasadjuncttoothermodalities,
and the identiﬁcation of active systemic therapies for certain
sarcoma subtypes [4–6].
Ewing’s sarcoma family of tumours (ESFTs) comprise an
aggressive group of sarcomas which can arise in soft tissue or
bone and include classical Ewing’s sarcoma, Askin tumour,
and primitive neuroectodermal tumour (PNET) [7]. These
tumours are most commonly diagnosed in adolescence [8],
although increasing numbers are being identiﬁed in adults
[9], have a slight male predominance, and are more common
in Caucasian populations [8, 9]. Approximately a quarter
of patients present with metastatic disease at the time of
diagnosis [10], and the most common metastatic sites are
lung (50%), bone (25%), and bone marrow (20%). Over
the last 30 years, the prognosis for patients with localised
disease has improved dramatically. The introduction of
combination chemotherapy has improved survival from
20%–30% (with surgery alone) to 60%–70% with multi
modality management [11]. Yet, the prognosis for patients
with metastatic or recurrent disease is very poor with only
30%–40% achieving a cure. Furthermore, the prognosis for
relapsing patients is very poor, with a 5-years survival rate
between 20% to 25% [12], and it is even worse in those who
relapseduringtheﬁrst24months[13,14].Therefore,thereis
an urgent need for developing better therapies to treat these
patients with very poor prognosis.2 Sarcoma
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Figure 1: The endocrine, paracrine and autocrine regulation of the IGF-1R pathway and therapeutic strategies for its disruption. (a),
Systemic regulation at the endocrine level. The GH-IGF-IGFBP is directed by the hypothalamus-hypophysis axis, where GH is produced,
and mediated by the hypothalamus GH releasing factors (which include GHRH and somatostatins). Disruption of the hypothalamus and
hypophysis axis, and thus GH release inhibition, has been attempted with somatostatin analogues (octeotride) in a Phase III trial [18].
However, this trial failed to meet the endocrinological and clinical endpoints. Pegvisomant (Pﬁzer) a human recombinant GH receptor
antagonist, has been tested successfully for the treatment of acromegaly [19]. This pegylated recombinant human analogue of GH can
decrease the production and release of IGF-I. Other strategies in preclinical development resulting in the reduction of the proportion of free
ligand include antiligand mAbs [20] or recombinant IGFBPs. (b) Free-ligand levels at tissue level are also regulated by the presence of the
diﬀerent IGFBPs. This ﬁgure illustrates the downstream signalling cascades that result in stimulation of the cell cycle and translation, leading
to increased proliferation and growth and inhibition of apoptosis. The IGF-1R pathway can be disrupted by using anti-IGF-1R mAbs and
tyrosine kinase inhibitors (TKIs). Another potential strategy is represented by the inhibition of downstream intracellular tyrosine kinase
proteins, that is, multiple small molecule inhibitors against PI3K, AKT, RAF, MEK, and mTOR inhibitors [21]. (Adapted from [22]).
The ESFTs family is characterised by speciﬁc chromo-
somal translocations involving the fusion of the EWS gene
and ETS family of transcription factors. The translocation
t(11;22) which results in the EWS-FLI1 fusion gene is the
commonest [15]. Work by Scotlandi and colleagues revealed
that IGF-1R system was activated in Ewing’s sarcoma cell
lines and tumours by an autocrine loop [16]. Subsequently,
Prieur and colleagues demonstrated the potential role of the
EWS-FLI1 fusion protein in Ewing’s sarcoma in the IGF-
1R pathway activation by repressing IGF-binding proteins
[17]. The aim of this manuscript is to review the preclinical
and clinical data supporting the use of IGF-1R inhibitors in
ESFTs.
2 .T h eI GF - 1 RP at h w a y
The IGF-1R pathway is more than a simple growth factor
receptor, its ligands and a downstream signalling cascade.
In vertebrates, it plays a key role in the growth and
development of normal tissues and regulates the overall
growth of organisms [23–25]. This pathway is also part of
a more complex insulin-related signalling network. In the
evolutionaryprocess,theinsulin-like growthfactorreceptors
and IGF system have developed from a single, common
ancestral receptor [26, 27] to a more complex system
which involves three ligands (IGF-I, IGF-II, and insulin)
and at least four receptors (IGF-1R, IGF-IIR, the insulin
receptor (IR), and hybrid receptors) [28]. A diagram of
the endocrine, paracrine, and autocrine regulation of this
pathway is represented in Figure 1.
The IGF-1R is a transmembrane receptor that is acti-
vated by IGF-1 and by the related growth factor IGF-2.
It is a tetrameric transmembrane receptor tyrosine kinase
composed of two α and two β subunits linked by disulﬁde
bonds. The extracellular α subunit is responsible for ligand
binding, whereas the β subunit consists of a transmembrane
domain and a cytoplasmic tyrosine kinase domain [29, 30].
The receptor is primarily activated by its cognate ligands,Sarcoma 3
insulin-like growth factor I (IGF-I) and II (IGF-II; 2- to
15-fold lower aﬃnity), and to a much lower aﬃnity by
insulin. The ligands bind to the cysteine-rich domain of
the α-subunits, leading to the transmission of a signal
through the transmembrane domain to the β-subunit. The
β-subunit responds by undergoing a conformational change
that causes stimulation of tyrosine kinase activity, followed
by autophosphorylation of a cluster of tyrosine residues
of the IGF-1R [31]. Then, IGF-1R activates alternative
pathways for protection from apoptosis, cell proliferation,
and diﬀerentiation. One of these pathways leads to the acti-
vation of PI3K-AKT-mTOR, while another pathway results
in MAPKs (mitogen-activated protein kinases) activation.
All these pathways, however, result in maintenance of cell
survival by antagonizing the processes and proteins involved
in apoptosis. This multiplicity of signalling pathways used by
the IGF-1R may explain why this receptor has such powerful
and widespread antiapoptotic activity [32–34].
3. Biological Implicationof the IGF-1R
Pathway inEwing’sSarcoma
The involvement of the IGF system in sarcoma initiation and
progression has been associated with postnatal development
[35, 36], primarily in those tumours that occur in younger
patients. During this growing period, the function of growth
hormone (GH) is mediated by IGF1. This is important, since
IGFs are important regulators of growth and development
in normal bone, contributing to about 50% of basal bone-
cell proliferation [37]. Therefore, overexpression of genes
involved in GH or IGF signalling may favour cell growth,
thus increasing the risk of tumorigenesis.
In the case of Ewing’s sarcoma, IGF-1R is ubiquitously
expressed and its activation is sustained by the autocrine
production of IGF1 by tumour cells [38, 39]. In vitro studies
have shown that IGF-1R is directly involved in Ewing’s
sarcomacellproliferationandsurvival[16,40–42].Ithasalso
been shown that EWS-FLI1, the genetic hallmark of Ewing
sarcoma, is only capable of transformation in the presence
of IGF-1R [43] and, more recently, that this fusion product
directly aﬀects IGF-1R signalling either by downregulating
IGFBP3 [17], increasing IGF1 promoter, or both [44]. Addi-
tionally,ithasbeenshownthatforcedexpressionofEWS-FLI
in mesenchymal stem cells resulted in transformation into a
phenotype similar to Ewing’s sarcoma. The cells transformed
by the fusion gene expressed high levels of IGF1 and were
dependent on IGF-1R signalling for growth and survival
[45]. Similarly, in mouse ﬁbroblasts, IGF-1R expression was
necessaryforEWS-FLI-mediatedtransformation[43].These
in vitro results have been conﬁrmed with the ﬁnding of IGF-
1R expression in clinical samples of Ewing’s sarcoma and
the demonstration that lower levels of IGF-1R expression
correlate with a lower tumor proliferative rate and a better
prognosis [46]. However, the limitations of this study in
terms of its retrospective nature and the antibodies used
should be noted. Despite such limitations, this observation is
important when planning clinical trials, where stratiﬁcation
of patients for biological variables may be important.
T h ee v i d e n c ed e s c r i b e da b o v es u p p o r t sar o l ef o rd r u g s
targeting IGF-1R signalling in Ewing’s sarcoma. Blockade of
IGF-1R has been shown to cause inhibition of cancer cell
proliferation, survival, and anchorage-independent growth
in vitro, to inhibit tumourigenesis, and block tumour
invasion and metastasis, and to sensitize cancer cells to
chemotherapy and radiotherapy [47].
4. PreclinicalExperienceTargeting IGF-1R
inEwing’sSarcomas
Despite the advances in the treatment of Ewing’s sarcoma,
many patients still succumb due to the development of
metastatic or recurrent disease, and there is recognition that
the beneﬁt achieved with conventional cytotoxic therapy has
reached a plateau. The need to identify and validate biologi-
callycriticaltargetsis,therefore,extremelyurgent.Toachieve
this aim, a large number of targeted therapeutic approaches
have been evaluatedin Ewing’s sarcoma models, both invitro
and in vivo. Some of these targets, including IGF-1R, have
been validated in preclinical studies and IGF-1R inhibitors
are currently undergoing evaluation in clinical trials. Among
the various strategies used to interfere with IGF-1R function
in preclinical studies, monoclonal antibodies (mAbs) and
small molecule tyrosine kinase inhibitors represent the best
candidates for clinical development.
Monoclonal antibodies need the following properties to
be eﬀective: they must inhibit binding of IGF1 and IGF2,
induce receptor downregulation, and have little or no eﬀect
on insulin receptor signalling. Promising in vitro and in
vivo studies have shown antitumor activity of several mAbs,
resulting in inhibition of proliferation, apoptosis induction,
and tumour growth inhibition [16, 48, 49].
There are a number of oral small molecule tyrosine
kinase inhibitors in development. In vitro studies with a
number of these agents have demonstrated inhibition of
IGF-1R, high level of growth inhibition, survival reduction,
complete pathway blockade, and xenograft tumor growth
reduction [41, 50–52]. However, receptor downregulation
was not observed with tyrosine kinase inhibitors, and this
may partly account for their cytostatic, rather than cytotoxic
eﬀects against Ewing’s sarcoma xenografts [53].
Whether or not complete IGF-1R selectivity should be
achieved is still under debate. Depending on the mechanism,
inhibition of IGF-1R may target not only IGF-1R itself
but also the hybrid receptors (especially those containing
the fetal isoform insulin receptor-A) which favour cancer
cell proliferation and are activated by both IGFs. It has
been shown that targeting IGF-1R increases the eﬃcacy
of other anticancer therapies. This is based on evidence
that IGF-1R signalling protects tumour cells from many
insults, including chemotherapeutic agents and ionizing
radiation [54–56], thus limiting the eﬃcacy of such therapy.
Inhibition of IGF-1R signalling has been shown to increase
the sensitivity of Ewing’s sarcoma cells to chemotherapy
[51, 57, 58]. Combining IGF1-R with conventional therapy
may have the advantage of lowering the eﬀective dosage
of radiotherapy and chemotherapy, minimizing side eﬀects4 Sarcoma
while maintaining eﬃcacy. This is particularly important
for paediatric patients. In addition to a potential role in
combination with traditional cytotoxic regimens and with
radiotherapy, there are data demonstrating involvement of
IGF-1R in trastuzumab resistance [59, 60] and resistance to
AKT/mTOR inhibitors [61]. It has been shown that IGF-1R
blockade can restore sensitivity to these agents.
An important issue in developing agents that speciﬁcally
target IGF-1R is its high level of homology with the
insulin receptor. There is a complete homology at the ATP-
binding pocket and 84% homology within the intracellular
kinase domain [62]. It is important to determine not only
overlapping but also diﬀerent biological eﬀects of both
receptors. Although both similarly activate PI3K and MAPK
pathways [63, 64], subtle diﬀerences exist in the recruitment
of certain docking proteins and intracellular mediators.
These diﬀerences may be exploitable in terms of developing
speciﬁc IGF-1R inhibitors. However, currently, there are no
published data speciﬁcally addressing the role of the insulin
receptor in Ewing’s sarcoma.
5.ClinicalExperiencewithIGF-1RTargeted
Treatments inEwing’sSarcoma
Atthetimeofthisreview,mAbsagainstIGF-1Rrepresentthe
most clinically advanced means of inhibiting this pathway in
thetreatmentofEwing’ssarcomapatients.Severalantibodies
have been tested in Phase II studies. Other approaches for
blocking or disrupting IGF-1R activity in Ewing’s sarcoma
patients include (a) the reduction of ligand levels or
bioactivity or (b) the inhibition of receptor function using
small-molecule tyrosine-kinase inhibitors [82]. Examples of
diﬀerent strategies for targeting the IGF-1R pathway are
represented in Figure 1.
Several anti-IGF-1R mAbs have been developed for
clinical use through the humanization of mouse mAbs,
immunization of genetically engineered mice that produce
fully human antibodies, or the selection of speciﬁc anti-
bodies from phage display libraries. These antagonistic IGF-
1R mAbs work through two major mechanisms: ﬁrst by
immediate inhibition of ligand binding, and secondly by
a delayed eﬀect on the downregulation of IGF-1R. At
present, eight diﬀerent mAbs have been evaluated in clinical
trials: ﬁgitumumab (CP-751,871), ganitumab (AMG479),
robatumumab (R1507), cixutumumab (IMC-A12), dalo-
tozumab (MK0646), SCH-717454, AVE-1642, and BIIB-022.
Other reviews have extensively discussed the diﬀerences and
similarities of these antibodies [22, 83]. In general, these
mAbs are IgG1 isotype [65, 73, 84–87] with the exception
of ﬁgitumumab and BIIB022 which are IgG2 [88]a n d
IgG4 [71] isotype, respectively. There are signiﬁcant phar-
macokinetic and immunologic diﬀerences between IgG1,
IgG2 and IgG4 isotypes. IgG2 mAbs appear to have longer
half-lives than IgG1 and IgG4 mAbs, while IgG1 mAbs
are usually potent activators of the classical complement
pathway, complement-dependent cell-mediated cytotoxicity
and antibody-dependent cellular cytotoxicity [89]. Table 1
reviews all the IGF-1R antibodies in clinical development.
5.1. Early Clinical Studies with Anti-IGF-1R Mabs Involving
Ewing Sarcoma Patients. To date, three early studies involv-
ing the evaluation of IGF-1R mAbs in Ewing’s sarcoma
have been published. The larger study, by Olmos et al.
[67], enrolled 29 patients with sarcoma, of which 15 had
refractory Ewing’s sarcoma. These patients were treated with
ﬁgitumumab at the recommended dose of 20mg/kg every
four weeks. These patients were heavily pretreated (median
of 3 lines), and notably 6 adolescent/paediatric patients
(over 12 years of age) were included in Ewing’s sarcoma
expansion cohort. Fourteen Ewing’s sarcoma patients were
evaluable for radiological response, and 2 durable and ongo-
ing radiological objective responses were observed, which
included a pathological complete response (CR) (currently,
36+ months) in a 12 year old male, and a partial response
(PR) (currently, 23+ months) in a young adult male (both
responses are illustrated in Figure 2). In addition, 6 and 4
Ewing’s sarcoma patients were free of disease progression
at 3 and 6 months, respectively. Furthermore, ﬁve of these
Ewing’s sarcoma patients with prolonged stable disease (SD)
had shrinkage of the target tumour lesions. Overall, the
nonprogression rate at 3 months was 53% (CI-95% 28–78)
and at 6 months was 40% (CI-95% 15–65) for all Ewing’s
sarcoma patients included in the study. However, as this was
a Phase I expansion cohort, it was not powered to formally
detect antitumour activity as a primary endpoint [67].
The second Phase I study, reported by Tolcher et al. [75],
studied the mAb ganitumab. This study included 12 adult
Ewing’s sarcoma patients who were treated with doses of
12 and 20mg/kg every 2 weeks. Ewing’s sarcoma patients
received ganitumab on days 1, 15, and 29; and this was
followed by a 28-day treatment-free period before resuming
the drug if tumour response was observed. One patient with
Ewing’s sarcoma attained a radiological CR which was main-
tained for 30 months. An additional Ewing’s sarcoma patient
achieved an unconﬁrmed PR but was withdrawn from the
study due to a myelodysplastic syndrome (non ganitumab
related). No other objectives responses or prolonged disease
stabilisation were reported [75].
A third mAb, R1507, has shown promising preliminary
activity in Ewing’s sarcoma. The Phase I study of a weekly
schedule of R1507 enrolled 9 Ewing’s sarcoma patients [73].
These patients were treated with doses ranging from 1mg/kg
to9mg/kgweekly.TwoEwing’ssarcomapatientshaddurable
PRs (lasting 11 and 26+ months), and a further 2 had SD
lasting for 4.3 and 6 months respectively.
Finally, a preliminary report of SCH-717454 was pre-
sented by Anderson et al. in the 2008 Annual Connective
Tissue Oncology Society (CTOS) Meeting [66]. This study
demonstratedradiologicalresponsesinpatientswithEwing’s
sarcoma [66]. This ongoing study included patients with
refractory/resistant Ewing’s sarcoma, as well as patients with
othersarcomasubtypeswhoweretreatedatadoseof9mg/kg
every week.
5.2. Phase II Studies with Anti-IGF-1R mAbs Involving Ewing
Sarcoma Patients. The exciting preliminary results with
anti-IGF-1R mAbs led to the development of a Phase IISarcoma 5
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Figure 2: Conﬁrmed responses to ﬁgitumumab in Ewing’s sarcoma. (a) This ﬁgure illustrates a response in a 12-year-old male patient
with metastatic Ewing’s sarcoma treated with ﬁgitumumab 20mg/kg every 4 weeks. The baseline, 6 and 32 cycle CT scans show a complete
response (conﬁrmed pathologically) in the target hilar mass and other subcentimeter lung nodules. (b) This ﬁgure illustrates a response in a
24-year-old male patient with metastatic extraskeletal Ewing’s sarcoma treated with ﬁgitumumab 20mg/kg every 4 weeks. The baseline and
cycle 4 CT scan demonstrate complete eradication of several <2cm lung metastases and a signiﬁcant reduction in the mediastinal mass. The
response to ﬁgitumumab was consolidated with 45Gy in 15 fractions. The patient has an ongoing partial response after 25 cycles. (Adapted
from [67]).
study in a variety of sarcoma subtypes, including Ewing’s
sarcoma, conducted by the Sarcoma Alliance for Research
through Collaboration (SARC) study group. This ambitious
study had 5 arms for speciﬁc sarcoma subtypes and had
a planned recruitment of approximately 300 patients. The
results of this study were reported during the 2010 American
Society of Clinical Oncology (ASCO) annual meeting [74].
A Green and Dahlberg two-stage design was employed
and the study included 111 Ewing’s sarcoma patients from
30 centres across North America and Europe. Patients
were treated with 9mg/kg weekly of R1507 and stratiﬁed
in two diﬀerent cohorts at study entry: poor prognosis
cohort (relapse/refractory disease <24 months and/or ≥2
chemotherapy regimens) which included 67 patients and a
good prognosis cohort (relapse ≥24 months and <2p r i o r
chemotherapy regimens) which included 44 patients. A total
of 10 conﬁrmed objective responses were observed using
WHO criteria [90], 1 CR, and 9 PRs. A further 7 patients
achieved unconﬁrmed partial responses but progressed
rapidly after the ﬁrst radiological evaluation. ObjectiveSarcoma 7
Table 2: Responses in clinical trials.
Drug N CR PR SD
Figitumumab
Phase I [67] 15 1 (7%) 1 (7%) 6 (40%)
Phase II [68] 106 0 15 (14%) 25 (24%)
R1507 Phase I
Phase I [73] 9 0 2 (22%) 2 (22%)
Phase II [74] 111 1 (1%) 7 (6%) 17 (15%)
Ganitumumab
Phase I [75] 12 1 (8%) 1 (8%) NA/NR
Phase II [76] 19 0 1 (5%) 7 (37%)
N = number of Ewing’s patients; = conﬁrmed complete response; PR: conﬁrmed partial responses; SD: stable disease (best response); NA/NR:
nonavailable/nonreported.
responses were equally distributed between the poor and
good prognosis cohorts (approximately 9% in both). The
median duration of response in these patients was 25 weeks
(range12–47).Afurther17patientshadconﬁrmedSDasthe
best response, 3 of these would have been deﬁned as PRs if
RECIST rather than WHO criteria had been employed [91].
The median overall survival (OS) for patients treated in this
study was 6.9 months.
A Phase II study of the IGF-1R mAb, ganitumab
(AMG479), in Ewing’s sarcoma and desmoplastic small
round cell tumour (DSRCT) patients was also presented at
the 2010 ASCO annual meeting [76]. The principal objective
of this study was to determine the objective response rate
(ORR) in patients who had not received prior therapy with
an IGF-1R inhibitor; however, there was an exploratory
cohort evaluating patients who had previously received
another anti-IGF-1R targeted therapy. All patients received
ganitumab at 12mg/kg every 2 weeks. A total of 19 Ewing’s
sarcoma patients entered the primary cohort, and 3 were
recruited to the exploratory cohort (no further data are
currently available). One Ewing’s sarcoma patient attained
a PR, and a further 7 Ewing’s patients achieved SD as best
response; however, only one of these remained progression
free beyond 24 weeks. The median progression-free survival
(PFS) for Ewing’s sarcoma patients included in this trial was
7.9 weeks.
More recently, Juergens et al. [68] presented the pre-
liminary results of a Phase 2 study of ﬁgitumumab in
paediatric (10 years or older) and adult patients with
refractory Ewing’s sarcomas. In this study, 106 patients were
evaluable for objective response (RECIST), 15 patients had
PRs, and 25 had stable disease. The median PFS for the
overall population was poor 1.9 months (CI-95% 1.8–2.1),
and the median overall survival was 8.9 months (CI-95%
7.2–10.8). However, in those patients with elevated blood
IGF-1 levels (>110ng/mL) at baseline, there was a signiﬁcant
advantage (P <. 001) in OS compared with those with low
IGF-1 (<110ng/mL), that is, 10.5 months and 4.5 months,
respectively.
To our knowledge, there are two further Phase II studies
of IGF1-R inhibition in Ewing’s: (1) a study of SCH717454
in Ewing’s sarcoma and osteosarcoma patients ≥4y e a r s
of age (http://www.clinicaltrials.gov/, NCT00617890) has a
planned recruitment of 190 patients and (2) a study of cixu-
tumumab (http://www.clinicaltrials.gov/, NCT00668148) in
185 patients (≥12 years) and ﬁvearms: Ewing’s sarcoma,
rhabdomyosarcoma, leiomyosarcoma, adipocytic sarcomas
and synovial sarcoma.
Despite the preclinical data and promising early clinical
results in Ewing’s sarcoma, the recent Phase II results
with anti-IGF-1R mAb as monotherapy have been less
impressive than initially hoped (Table 2). Preliminary data
for the mTOR inhibitor, radiforolimus (previously known
as deferolimus), have shown a nonprogression rate of 30%
at 16 weeks in bone sarcomas [21]. The mTOR inhibitor
was deemed active and a Phase III trial comparing radi-
forolimus with placebo, as maintenance therapy, has recently
completed recruitment. Other targeted agents have also
been explored, and in a recent trial of imatinib in various
sarcoma subtypes, no clinical activity was seen in patients
with Ewing’s sarcoma [92].
TheresultsofPhaseIIstudiespublishedtodatehavebeen
disappointing, and the clinical development pathway for this
class of agents is currently very uncertain. Furthermore, the
poor results observed with these agents in lung cancer have
led to Roche halting further development of R1507 in all
tumours [93, 94]. However, there is still the promise that
these agents may have a role in the management of Ewing’s
sarcoma, either as monotherapy in selected patients or in
combination regimens.
5.3. Toxicity with IGF-1R Monoclonal Antibodies. In general,
IGF-1R mAbs are well tolerated, with the most common
toxicities being mild and occasionally moderate. Severe
(grade3)orlife-threatening(grade4)adverseeventsarerare.
Potential grade 3 and 4 hematologic adverse events reported
in the Phase II trial with ganitumumab and R1507 included
thrombocytopenia [74, 76], anemia [74, 76], neutropenia
[76], pain at the time of administration [74], hyponatremia
[74], and hyperglycemia [74, 76]. Thrombocytopenia was
also reported in Phase I studies [69, 73, 75]. Grade 38 Sarcoma
and 4 nonhematologic adverse events with ﬁgitumumab in
sarcoma patients included deep venous thrombosis (n = 1),
vomiting (n = 1), and back pain (n = 1). Grade 3 fatigue
was also reported with ﬁgitumumab in nonsarcoma patients
[95, 96]. Other relevant grade 3-4 nonhematological adverse
events described with other IGF-1R mAbs include fatigue
[72, 75, 97], arthralgia [75], chills [72], pneumonitis [69],
nausea or vomiting [72], rash and/or pruritus [72], pain
[66, 72], and gastrointestinal bleeding [69].
Hyperglycaemia is a common toxicity of all the mAbs,
with grade 3 hyperglycaemia seen in several studies [66,
72, 97]. The mechanism for hyperglycaemia is unclear
although IGF-1R may be involved in glucose metabolism
via crosstalk and heterodimerisation with the insulin recep-
tor [98–101]. This observation, and the increased plasma
insulin levels reported after treatment with IGF-1R mAbs
[96, 102], suggests compensatory insulin secretion and
associated insulin resistance, the latter possibly secondary to
increasedIGF-1andgrowth-hormonelevels[82,103].Other
severelaboratoryabnormalitiesobservedinsarcomapatients
include uric acid elevation and transaminitis [67].
Interestingly,despitetheexpressionofIGF-1Rinvascular
smooth muscle and endothelial cells [104] and the potential
cardiotoxicity associated with mAbs, no cardiac toxicity has
been reported to date. In the case of sarcoma patients treated
with ﬁgitumumab, it is noteworthy that three-quarters of
the patients were pretreated with anthracyclines and none
developed cardiotoxicity [67].
Theoretically, IGF-1R mAbs would be expected to have
an inhibitory eﬀect on IGF and growth hormone-mediated
growth. Thus, IGF-1R blockade could cause linear and
somaticgrowthdelayinachildhoodandteenagepopulation,
as supported by the identiﬁcation of patients with genetic
defects in the IGF-1 axis such as IGF-1 deﬁciency [105]. This
potential long-term adverse event is extremely important in
the management of young sarcoma patients [1]. The current
clinical experience is too limited to deﬁnitively address this
question [67]. Detailed assessments of growth and hormone
levelshavebeenincludedinongoingPhaseIItrialsrecruiting
paediatric and prepubertal teenage patients, and it is hoped
that these studies will provide insights to the eﬀect of IGF-1R
targeted therapy on growth during childhood and puberty.
5.4. Early Experience with Tyrosine Kinase Inhibitors of IGF1-
R. There are a number of small molecule tyrosine kinase
inhibitors (TKIs) of IGF1-R that are currently being, or have
been,evaluated(Table 1).Someofthesesmallmoleculesalso
inhibit IR-A, a component of IGF-R hybrid receptors [83].
Although this can potentially result in greater antitumour
activity, it may also be associated with a higher incidence
of metabolic toxicity. From the results of clinical trials of
monoclonal antibodies and tyrosine kinase inhibitors in
other tumour types, it is apparent that predicting diﬀerences
in eﬃcacy between these two classes can be diﬃcult [106].
Notably, small molecule tyrosine kinase inhibitors do not
directly activate the immune response against tumour cells,
but they may be more eﬀective when activated receptors are
localised in cytoplasmic caveosomes and/or endosomes.
Some of these novel IGF-1R TKIs (i.e., picropodophylin
(PPP), GSK183870A, GSK1904529A, BMS-536924, NVP-
AEW541) have already shown promising preclinical activity
as single agents or in combination in diﬀerent sarcoma
models [50, 51, 53, 79, 81, 107–109]. At the present time,
only OSI-906 has been tested in Ewing’s sarcoma patients
(n = 2) although no antitumor activity was seen in these
two cases [77]. However, currently there are insuﬃcient data
to deﬁne any diﬀerence in clinical beneﬁt in patients treated
with these two classes of IGF1-R inhibitors.
5.5. Combination Therapy with IGF-1R mAbs. IGF-1R acti-
vation has been associated with chemoresistance in multiple
cancers [110], including some sarcomas such as Ewing’s
sarcoma [39]. Indeed, modulation of IGF signalling has
been shown to enhance the antitumor activity of cytotoxic
drugs in laboratory sarcoma models [58]. Thus, a strategy
based on the combination of ﬁrst- or second-line sarcoma
chemotherapy with IGF-1R mAbs seems a rational approach
in the utilisation of these agents. Currently, there are a
number of ongoing or planned studies evaluating such
combinations, including a Phase I/II trial of cixutumumab
in combination with doxorubicin for advanced and unre-
sectable soft-tissue sarcomas (http://www.clinicaltrials.gov/,
NCT00720174), sponsored by the National Cancer Insti-
tute and a Phase I of SCH-717454 in combination with
diﬀerent commonly used chemotherapies in sarcoma such
as vincristine, doxorubicin, and cyclophosphamide (CAV)
or ifosfamide and etoposide (http://www.clinicaltrials.gov/,
NCT00960063).
Furthermore, clinical studies of rational combinations
of IGF-1R mAbs with other targeted therapies are in
progress. Examples of such regimens are the use of mTOR
inhibitors in combination with IGF-1R antibodies [49,
111]. Studies evaluating this approach include a trial of
RAD001 (everolimus) in combination with ﬁgitumumab
sponsored by the Dana-Faber Cancer Institute [112]. This
study enrolled a total of 21 sarcoma patients one of whom
had Ewing’s sarcoma. The reported toxicity proﬁle for this
combination was not signiﬁcantly diﬀerent from that of
single agent everolimus. Grade 3 toxicity occurred in ≤10%
of patients, and included mucositis, nausea, vomiting, and
diarrhoea. One patient with Ewing’s sarcoma maintained
stable disease for six months. In addition, a trial of tem-
sirolimus with cixutumumab (http://www.clinicaltrials.gov/,
NCT01016015) is actively recruiting sarcoma patients. Other
rational combinations could include regimens with heat
shock protein 90 [113] or EGFR/HER2 inhibitors [107],
as these have been implicated in potential mechanisms of
resistance to IGF-1R inhibition in sarcoma cell lines.
5.6. Patient Selection. Despite robust preclinical evidence
supporting the role of IGF1-R-targeted agents in Ewing’s
sarcoma, clinical results show that only a proportion of
patients derive signiﬁcant beneﬁt, with many progressing
early, even after an initial response. Although initial reports
suggested an association between the EWS/FLI-1 type 1
translocation and response in Ewing’s sarcoma [75], theSarcoma 9
purportedpredictivevalueoftranslocationtypehasnotbeen
observed consistently [67, 74, 76]. Clinical data in nonsmall
cell lung cancer patients have suggested that circulating free
IGF-1 may identify patients who derive clinical beneﬁt from
ﬁgitumumab [114]. Similar data has also been reported
in the Phase II trial of ﬁgitumumab in refractory Ewing’s
sarcoma, in which patients with elevated IGF-1 at baseline
achieved longer OS [68]. However, it still remains unclear
if an elevated IGF-1 level at baseline is a predictive factor
for response to IGF-1R antibodies or simply a prognostic
factor. Nonetheless, as IGF system and the activation of the
IGF1-R are complex, response and resistance mechanisms
are unlikely to be entirely dependent on or explained by
circulating IGF-1 [115, 116].
6. Conclusions
During the last two decades, large amounts of preclinical
data have been accumulated supporting the use of agents
targetingIGF-1R in Ewing’s sarcoma.This rationalehasbeen
reinforced by the early reports of clinical activity with several
IGF-1R antibodies in this disease. However, the beneﬁt of
this therapeutic approach clearly does not extend to all
patients, with Phase II studies demonstrating less promising
responses than initially anticipated. In addition to the
exploration of IGF-1R in combination with chemotherapy
and other targeted agents, there is an urgent need to identify
predictive biomarkers to improve patient selection, as well
as to elucidate the mechanisms of resistance to these drugs,
thereby facilitating the development of rational combination
regimens. Despite the disappointing Phase II data, this novel
group of drugs does constitute an active treatment in a
proportion of Ewing’s sarcoma patients.
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